Smart Insulin Pens - Market Insights, Competitive Landscape, and Market Forecast - 2034

Smart Insulin Pens Market Summary

Overview:

• The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034. Growth is anchored in the rising global burden of diabetes, growing patient and physician preference for connected, data-driven insulin delivery, and expanding integration between smart pens, continuous glucose monitors (CGMs), and digital diabetes-management platforms.
• The global Smart Insulin Pens market is growing at a CAGR of 11.4% during the forecast period from 2026 to 2034.
• By connectivity type, the Bluetooth-Enabled segment dominated the Smart Insulin Pens market with a 63% share in 2025.
• By end-user, the Hospitals & Clinics segment dominated the Smart Insulin Pens market with a 41% share in 2025.
• By distribution channel, the Hospital & Retail Pharmacy segment dominated the Smart Insulin Pens market with a 53% share in 2025.
• North America dominated the global Smart Insulin Pens market revenue with a 44% share in 2025, representing the highest regional market share globally.

A smart insulin pen is a reusable or disposable insulin delivery device, or a connected add-on cap for a conventional pen, that automatically captures the dose, date, and time of each injection and transmits this information via Bluetooth, NFC, USB, or cloud connectivity to a companion mobile application. By digitizing insulin dosing, these devices support dose-tracking, missed-dose alerts, bolus calculation, insulin-on-board estimation, and integration with continuous glucose monitors, helping people with diabetes and their clinicians make more informed, data-backed treatment decisions. The market is organized by connectivity type across Bluetooth-enabled, NFC-enabled, USB-connected, and wireless/cloud-connected pens; by end-user, spanning hospitals and clinics, homecare settings, diabetes specialty centers, and ambulatory care centers; and by distribution channel, including hospital and retail pharmacies, diabetic clinics and centers, and e-commerce. Driven by the surging global diabetes population, rising demand for personalized digital diabetes management, and accelerating device-to-app and device-to-CGM connectivity, smart insulin pens are becoming an increasingly central component of the connected diabetes-care ecosystem.

Smart Insulin Pens Market Key Growth Drivers

• The rising global burden of diabetes is expanding the addressable patient population, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024, a figure projected to reach 853 million by 2050.
• Growing physician and patient preference for connected insulin delivery over conventional pens is accelerating adoption, as automatic dose-logging reduces missed or duplicated doses and improves treatment adherence.
• Expanding integration between smart insulin pens and continuous glucose monitoring systems, such as Medtronic InPen's compatibility with Dexcom and FreeStyle Libre sensors, is creating a data-rich, near-closed-loop management experience for people on multiple daily injections.
• Major insulin manufacturers, including Novo Nordisk, Sanofi, and Eli Lilly, are embedding connectivity directly into their branded insulin delivery ecosystems to strengthen patient retention and support value-based care contracting.
• Rising smartphone penetration and the proliferation of diabetes-management apps are lowering the adoption barrier for connected pens, particularly in homecare and ambulatory settings.
• Favorable reimbursement developments and expanding insurance coverage for connected insulin delivery devices in the United States and parts of Europe are improving affordability and prescription volumes.
• Growing merger, acquisition, and licensing activity, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is consolidating smart-pen technology within larger diabetes-care and pharmaceutical platforms and accelerating commercialization.

Key Companies in Smart Insulin Pens Market

The competitive landscape is led by the following active manufacturers:

• Emperra GmbH E-Health Technologies
• Jiangsu Delfu Medical Device Co., Ltd.
• Medtronic
• Novo Nordisk A/S
• Pendiq
• Sanofi
• Berlin-Chemie
• Bigfoot Biomedical
• Digital Medics Pty Ltd.
• Eli Lilly and Company

Factors Contributing to the Growth of the Smart Insulin Pens Market

Market Drivers

Rising Global Diabetes Burden and Insulin-Dependent Population

The single most powerful driver of the Smart Insulin Pens market is the sheer scale and continued growth of the global diabetes population. The International Diabetes Federation estimates that 589 million adults were living with diabetes in 2024, equivalent to roughly one in nine adults worldwide, with the figure projected to rise to 853 million by 2050. A substantial share of this population, spanning both type 1 diabetes and insulin-requiring type 2 diabetes, relies on multiple daily insulin injections delivered by pen, creating a large and expanding installed base for connected pen technology. As insulin-treated populations grow across both developed and emerging markets, and as clinicians increasingly seek objective dosing data to guide therapy intensification, demand for smart insulin pens that automatically capture and transmit dosing information expands in step, anchoring market growth through 2034.

Growing Demand for Personalized, Data-Driven Diabetes Management

Smart insulin pens address a long-standing gap in diabetes care: the absence of objective, real-time insulin dosing data comparable to what continuous glucose monitors already provide for glucose levels. By automatically logging the size and timing of every injection, these devices eliminate manual dose diaries, reduce missed or duplicated doses, and allow both patients and healthcare providers to review injection history alongside glucose trends. This capability supports more personalized dose titration, better identification of patterns such as skipped basal doses, and more productive clinic visits. As payers and providers increasingly emphasize value-based, data-informed diabetes care, demand for the objective dosing record that smart pens provide continues to strengthen across both type 1 and type 2 diabetes populations.

Market Restraints

Despite strong underlying momentum, the Smart Insulin Pens market faces material constraints. The higher upfront and per-unit cost of smart pens and connected add-on caps relative to conventional insulin pens remains a barrier to adoption, particularly in price-sensitive and emerging markets where out-of-pocket healthcare spending is high. Reimbursement for connected insulin delivery devices remains inconsistent across geographies, and coverage gaps can leave patients responsible for costs that limit uptake even where clinical benefit is well established. Data privacy and cybersecurity concerns associated with the transmission and storage of personal health and dosing information create hesitancy among some patients and providers, and interoperability challenges between different manufacturers' pens, apps, and CGM systems can fragment the user experience and complicate clinical workflows. Limited awareness of smart-pen technology among patients and even some healthcare providers in low- and middle-income regions constrains penetration outside established markets, and reliance on smartphone pairing excludes patients without consistent smartphone access. Eli Lilly's 2026 decision to discontinue its Tempo Personalized Diabetes Management Platform underscores the commercial and reimbursement uncertainty that can affect even well-resourced connected-pen programs. Together, these cost, reimbursement, data-security, interoperability, and awareness barriers temper the pace of adoption, even as the underlying drivers of rising diabetes prevalence and digital health adoption remain firmly intact.

Smart Insulin Pens Market Segment Analysis

The smart insulin pens market by connectivity type (bluetooth-enabled, nfc-enabled, usb-connected, wireless/cloud-connected), end-users (hospitals & clinics, homecare settings, diabetes specialty centers, ambulatory care centers, others), distribution channels (hospital & retail pharmacy, diabetic clinics & centers, e-commerce, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Connectivity Type

Dominant Subsegment: Bluetooth-Enabled.

The Bluetooth-enabled segment accounted for 63% of the Smart Insulin Pens market in 2025. Bluetooth-enabled pens are the leading connectivity type because Bluetooth Low Energy offers reliable, low-power, continuous pairing with smartphones, enabling automatic, real-time transfer of dosing data without requiring the patient to actively tap or scan the device. Leading products such as Medtronic's InPen, Novo Nordisk's NovoPen 6 and NovoPen Echo Plus, and Eli Lilly's Tempo Smart Button all rely on Bluetooth connectivity, giving the segment the deepest catalog of commercially available, clinically validated devices. Bluetooth's broad compatibility with both iOS and Android diabetes-management apps, together with its established role in CGM data transmission, makes it the natural default for manufacturers building integrated glucose-and-insulin data platforms. While NFC-enabled pens are the fastest-growing connectivity type, valued for their simplicity and lower power requirements in markets such as Germany where Emperra's ESYSTA pioneered Bluetooth-enabled dosing, the breadth of Bluetooth's device ecosystem and its central role in CGM integration secure the segment's leadership across the forecast period.

By End-Users

Dominant Subsegment: Hospitals & Clinics.

The hospitals & clinics segment accounted for 41% of the Smart Insulin Pens market in 2025. Hospitals and clinics are the leading end-user category because they serve as the primary point of diabetes diagnosis, insulin therapy initiation, and device prescription, giving endocrinologists and diabetes educators direct influence over which connected pens patients adopt. Clinical settings also generate the greatest immediate value from objective dosing data, since physicians use pen-generated injection histories to titrate therapy, identify adherence gaps, and support insurance documentation during in-person visits. Hospitals and specialty diabetes clinics were also the first sites to pilot smart-pen programs such as the Bigfoot Unity Program, reinforcing clinical familiarity and referral pathways. While homecare settings are the fastest-growing end-user category as more patients self-manage therapy at home with continuous app-based support, the central role of hospitals and clinics in device prescription and therapy titration secures the segment's leadership across the forecast period.

Smart Insulin Pens Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of diagnosed diabetes, strong insurance and reimbursement coverage for connected insulin delivery devices, and the presence of leading manufacturers including Medtronic, Eli Lilly, and Abbott (following its acquisition of Bigfoot Biomedical). The United States in particular benefits from broad adoption of the InPen and Bigfoot Unity systems, extensive CGM penetration that creates natural pull-through demand for CGM-compatible smart pens, and FDA clearance pathways that have supported a steady stream of new connected-device launches. Strong direct-to-consumer digital health marketing, employer and payer-sponsored diabetes management programs, and deep integration with popular diabetes apps further reinforce the region's leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Smart Insulin Pens market. The region's elevated CAGR is driven by its enormous and rapidly growing diabetic population, led by China and India, alongside rising healthcare expenditure, expanding private insurance coverage, and growing local manufacturing capability. China's Jiangsu Delfu Medical Device Co., Ltd. is scaling domestic production of connected insulin delivery devices, Japan is seeing steady adoption of digital diabetes-management tools within its advanced healthcare system, and India's large and increasingly urban diabetic population is driving demand for affordable connected pens and smart-cap add-ons. Government initiatives to modernize chronic-disease management and growing awareness of digital health tools among both patients and physicians are accelerating adoption, positioning Asia-Pacific as the principal source of incremental market growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025. The United States dominates on the strength of its high diagnosed-diabetes prevalence, favorable device reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott, while Canada contributes steady growth supported by its public healthcare system's gradual expansion of connected-device coverage.

Europe

Europe is a large and technologically advanced regional market, anchored by Germany, home to Emperra GmbH E-Health Technologies, whose ESYSTA pen was among the first Bluetooth-enabled smart insulin pens to receive European Commission approval, and Pendiq, another German developer of connected insulin delivery devices. Berlin-Chemie and Sanofi's SoloSmart, developed with Biocorp, extend the region's connected-pen footprint across Germany, France, the United Kingdom, Italy, and Spain, supported by established EU medical device regulatory frameworks and growing statutory health-insurance coverage for digital diabetes tools.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by its large and expanding diabetic population across China, Japan, India, South Korea, and Australia. China's Jiangsu Delfu Medical Device Co., Ltd. is expanding domestic manufacturing and distribution of connected insulin pens, Japan's advanced healthcare infrastructure supports steady premium-device adoption, and India's growing private healthcare and insurance sector is broadening access to smart insulin delivery technology, together accelerating regional market growth.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier for smart insulin pens. Rising diabetes prevalence, gradually improving healthcare infrastructure, and growing awareness of digital diabetes-management tools, led by companies such as Digital Medics Pty Ltd., extending connectivity solutions into new markets, are broadening access, while international distribution partnerships and expanding private insurance coverage support the gradual build-out of regional demand.

Smart Insulin Pens Market Competitive Landscape

The Smart Insulin Pens market is classified as Moderately Fragmented. A group of large, diversified medical device and pharmaceutical companies with global distribution, including Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company, anchor the top tier by embedding connectivity into branded insulin ecosystems, while specialized connected-device developers such as Emperra GmbH E-Health Technologies, Pendiq, Berlin-Chemie, Bigfoot Biomedical, Jiangsu Delfu Medical Device Co., Ltd., and Digital Medics Pty Ltd. compete through focused smart-cap and smart-pen innovation, regional manufacturing strength, and niche connectivity partnerships.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately fragmented, with large insulin and device manufacturers leading distribution scale alongside specialized connected-pen innovators.
• Leading players: Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company anchor the top tier through branded insulin ecosystem integration and global reach.
• Geographic reach: Leaders operate global distribution networks, while regional specialists such as Emperra, Pendiq, and Berlin-Chemie maintain strong footholds in the German and broader European market.
• Product portfolio strength: Top players offer integrated pen-plus-app-plus-CGM ecosystems spanning dose logging, bolus calculation, and insulin-on-board tracking.
• Connectivity technology: Ownership of validated Bluetooth, NFC, and cloud-connectivity platforms, together with CGM interoperability, is a decisive competitive advantage.
• Strategic partnerships: Tie-ups between insulin manufacturers and device or app developers, such as Sanofi and Biocorp's SoloSmart and Medtronic InPen's Dexcom and FreeStyle Libre integrations, extend ecosystem reach.
• M&A activity: Active consolidation, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is concentrating connected-pen technology within larger diabetes-care platforms.
• Manufacturing capabilities: Precision dose-sensing electronics, miniaturized Bluetooth and NFC modules, and regulatory-grade quality manufacturing are key competitive moats.
• Innovation focus: CGM integration, AI-assisted dose guidance, expanded smartphone and wearable compatibility, and next-generation smart-cap retrofits for disposable pens.

Smart Insulin Pens Market Recent Developmental Activities

In 2026, Eli Lilly and Company announced the discontinuation of its Tempo Personalized Diabetes Management Platform, including the Tempo Smart Button, Tempo Pens, and TempoSmart app, by the end of 2026, shifting affected patients toward standard KwikPen insulin delivery and the Lilly Insulin Value Savings Card. Strategic significance: Signals the commercial and reimbursement challenges connected-pen programs can face even when backed by a major insulin manufacturer.

Smart Insulin Pens Market Segmentation

Smart Insulin Pens Market by Connectivity Type

• Bluetooth-Enabled
• NFC-Enabled
• USB-Connected
• Wireless/Cloud-Connected

Smart Insulin Pens Market by End-Users

• Hospitals & Clinics
• Homecare Settings
• Diabetes Specialty Centers
• Ambulatory Care Centers
• Others

Smart Insulin Pens Market by Distribution Channels

• Hospital & Retail Pharmacy
• Diabetic Clinics & Centers
• E-commerce
• Others

Smart Insulin Pens Market by Geography

• North America Smart Insulin Pens Market
• United States Smart Insulin Pens Market Size in USD million (2023-2034)
• Canada Smart Insulin Pens Market Size in USD million (2023-2034)
• Mexico Smart Insulin Pens Market Size in USD million (2023-2034)
• Europe Smart Insulin Pens Market
• Germany Smart Insulin Pens Market Size in USD million (2023-2034)
• United Kingdom Smart Insulin Pens Market Size in USD million (2023-2034)
• France Smart Insulin Pens Market Size in USD million (2023-2034)
• Italy Smart Insulin Pens Market Size in USD million (2023-2034)
• Spain Smart Insulin Pens Market Size in USD million (2023-2034)
• Rest of Europe Smart Insulin Pens Market Size in USD million (2023-2034)
• Asia-Pacific Smart Insulin Pens Market
• China Smart Insulin Pens Market Size in USD million (2023-2034)
• Japan Smart Insulin Pens Market Size in USD million (2023-2034)
• India Smart Insulin Pens Market Size in USD million (2023-2034)
• Australia Smart Insulin Pens Market Size in USD million (2023-2034)
• South Korea Smart Insulin Pens Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Smart Insulin Pens Market Size in USD million (2023-2034)
• Rest of the World (RoW) Smart Insulin Pens Market
• Middle East Smart Insulin Pens Market Size in USD million (2023-2034)
• Africa Smart Insulin Pens Market Size in USD million (2023-2034)
• South America Smart Insulin Pens Market Size in USD million (2023-2034)

Key Takeaways from the Smart Insulin Pens Market Report Study

• Market size analysis for the current Smart Insulin Pens market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global Smart Insulin Pens market.
• Various opportunities available for competitors in the Smart Insulin Pens market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Smart Insulin Pens market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Smart Insulin Pens market growth in the future?

Target audience who can benefit from this Smart Insulin Pens market report study

• Smart Insulin Pens product providers
• Research organizations and consulting companies
• Smart Insulin Pens therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Smart Insulin Pens
• Various end-users who want to know more about the Smart Insulin Pens market and the latest technological developments in the Smart Insulin Pens market.

Frequently Asked Questions:

Q1. What is the growth rate of the Smart Insulin Pens market?

The Smart Insulin Pens market is projected to expand at a CAGR of 11.4% during the forecast period from 2026-2034.

Q2. What is the market size of the Smart Insulin Pens market?

The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034.

Q3. Which region dominates the Smart Insulin Pens market?

North America dominated the Smart Insulin Pens market with a 44% share of global revenue in 2025, supported by high diagnosed diabetes prevalence, favorable reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Smart Insulin Pens market?

The principal drivers are the rising global burden of diabetes, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024 and projecting 853 million by 2050; growing demand for personalized, data-driven diabetes management; expanding integration between smart pens and continuous glucose monitoring systems; strategic investment by major insulin manufacturers; rising smartphone and digital health app penetration; and accelerating consolidation and M&A activity.

Q5. Who are the major players in the Smart Insulin Pens market?

The major players include Emperra GmbH E-Health Technologies, Jiangsu Delfu Medical Device Co., Ltd., Medtronic, Novo Nordisk A/S, Pendiq, Sanofi, Berlin-Chemie, Bigfoot Biomedical, Digital Medics Pty Ltd., and Eli Lilly and Company, among other active providers profiled in the Competitive Landscape section. Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company lead through branded insulin ecosystem integration and global distribution reach.